2016 was a banner year for innovative pharma firms in China, in which startups like BeiGene and Betta successfully gained public listings, while others including Ascentage and Innovent Bio bagged major new funding. So what are seasoned executives and investors now looking for in the next wave of innovators and what are the risk factors?
The policy message is clear. Innovation is the new key word for the pharma industry in China, according to industry experts and investors at a recent healthcare investment forum in the country.
“In 2016, innovation essentially became the core competitive advantage for the China drug-making sector,” declared Helen Chui, managing director of...
The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
